Journal of Clinical Oncology, Vol 15, 2296-2301, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

Predictive capacity of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma

SM Ansell, TM Habermann, PJ Kurtin, TE Witzig, MG Chen, CY Li, DJ Inwards and JP Colgan
Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA.

PURPOSE: The International Prognostic Factor Index has been shown to predict the outcome of patients with predominantly B-cell lymphomas classified using traditional classifications, including the Working Formulation, but its prognostic importance has not been tested in a cohort of patients with exclusively T-cell lymphomas. This study was conducted to evaluate the prognostic significance of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma (PTCL). PATIENTS AND METHODS: Seventy-eight patients (48 men and 30 women) with PTCL seen at a single institution between 1985 and 1995 were included in the analysis. The morphology and immunocytochemistry of all the original biopsy specimens were reviewed by a single pathologist and classified using the Revised European-American Lymphoma (REAL) classification. The International Prognostic Factor Index, as well as clinical and biochemical parameters, were evaluated by univariate and multivariate analyses to determine their association with patient outcome. RESULTS: The International Prognostic Factor Index strongly predicted survival when all patients were included in the analysis (P < .001). For patients < or = 60 years, the age-adjusted International Index significantly predicted long-term survival (P = .0218). For patients older than 60 years, the age-adjusted International Index also significantly predicted survival (P = .002). Liver involvement (P = .006) and bone marrow involvement (P = .014) were also significant prognostic factors in the univariate analysis, but only the International Index remained significant in the multivariate analysis (P = .001). CONCLUSION: The International Prognostic Factor Index, which significantly predicts outcome in patients with aggressive/intermediate-grade B-cell lymphomas, has similar prognostic importance in patients with PTCL.

This article has been cited by other articles:

				P. Reimer, T. Rudiger, E. Geissinger, F. Weissinger, C. Nerl, N. Schmitz, A. Engert, H. Einsele, H. K. Muller-Hermelink, and M. Wilhelm Autologous Stem-Cell Transplantation As First-Line Therapy in Peripheral T-Cell Lymphomas: Results of a Prospective Multicenter Study J. Clin. Oncol., January 1, 2009; 27(1): 106 - 113. [Abstract] [Full Text] [PDF]

				A. Gallamini, F. Zaja, C. Patti, A. Billio, M. R. Specchia, A. Tucci, A. Levis, A. Manna, V. Secondo, L. Rigacci, et al. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial Blood, October 1, 2007; 110(7): 2316 - 2323. [Abstract] [Full Text] [PDF]

				M. Cuadros, S. S. Dave, E. S. Jaffe, E. Honrado, R. Milne, J. Alves, J. Rodriguez, M. Zajac, J. Benitez, L. M. Staudt, et al. Identification of a Proliferation Signature Related to Survival in Nodal Peripheral T-Cell Lymphomas J. Clin. Oncol., August 1, 2007; 25(22): 3321 - 3329. [Abstract] [Full Text] [PDF]

				P. Went, C. Agostinelli, A. Gallamini, P. P. Piccaluga, S. Ascani, E. Sabattini, F. Bacci, B. Falini, T. Motta, M. Paulli, et al. Marker Expression in Peripheral T-Cell Lymphoma: A Proposed Clinical-Pathologic Prognostic Score J. Clin. Oncol., June 1, 2006; 24(16): 2472 - 2479. [Abstract] [Full Text] [PDF]

				T. M. Kim, Y. H. Park, S.-Y. Lee, J.-H. Kim, D.-W. Kim, S.-A. Im, T.-Y. Kim, C. W. Kim, D. S. Heo, Y.-J. Bang, et al. Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage IE/IIE extranodal NK/T-cell lymphoma, nasal type Blood, December 1, 2005; 106(12): 3785 - 3790. [Abstract] [Full Text] [PDF]

				K. J. Savage, M. Chhanabhai, R. D. Gascoyne, and J. M. Connors Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification Ann. Onc., October 1, 2004; 15(10): 1467 - 1475. [Abstract] [Full Text] [PDF]

				J.-Y. You, K.-H. Chi, M.-H. Yang, C.-C. Chen, C.-H. Ho, W.-K. Chau, H.-C. Hsu, J.-P. Gau, C.-H. Tzeng, J.-H. Liu, et al. Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)/T-cell lymphoma: a single institute survey in Taiwan Ann. Onc., April 1, 2004; 15(4): 618 - 625. [Abstract] [Full Text] [PDF]

				A. Gallamini, C. Stelitano, R. Calvi, M. Bellei, D. Mattei, U. Vitolo, F. Morabito, M. Martelli, E. Brusamolino, E. Iannitto, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study Blood, April 1, 2004; 103(7): 2474 - 2479. [Abstract] [Full Text] [PDF]

				C.-S. Chim, S.-Y. Ma, W.-Y. Au, C. Choy, A. K. W. Lie, R. Liang, C.-C. Yau, and Y.-L. Kwong Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index Blood, January 1, 2004; 103(1): 216 - 221. [Abstract] [Full Text] [PDF]

				T. Rudiger, D. D. Weisenburger, J. R. Anderson, J. O. Armitage, J. Diebold, K. A. MacLennan, B. N. Nathwani, F. Ullrich, and H. K. Muller-Hermelink Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project Ann. Onc., January 19, 2002; 13(1): 140 - 149. [Abstract] [Full Text] [PDF]

				L. F. Porrata, M. A. Gertz, D. J. Inwards, M. R. Litzow, M. Q. Lacy, A. Tefferi, D. A. Gastineau, A. Dispenzieri, S. M. Ansell, I. N. M. Micallef, et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma Blood, August 1, 2001; 98(3): 579 - 585. [Abstract] [Full Text] [PDF]

				J. P. Greer, M. C. Kinney, and T. P. Loughran Jr. T Cell and NK Cell Lymphoproliferative Disorders Hematology, January 1, 2001; 2001(1): 259 - 281. [Abstract] [Full Text] [PDF]

				P. L. Zinzani, G. Baliva, M. Magagnoli, M. Bendandi, G. Modugno, F. Gherlinzoni, G. F. Orcioni, S. Ascani, R. Simoni, S. A. Pileri, et al. Gemcitabine Treatment in Pretreated Cutaneous T-Cell Lymphoma: Experience in 44 Patients J. Clin. Oncol., July 1, 2000; 18(13): 2603 - 2606. [Abstract] [Full Text] [PDF]

				M. B. Moller, A.-M. Gerdes, K. Skjodt, L. S. Mortensen, and N. T. Pedersen Disrupted p53 Function as Predictor of Treatment Failure and Poor Prognosis in B- and T-Cell Non-Hodgkin's Lymphoma Clin. Cancer Res., May 1, 1999; 5(5): 1085 - 1091. [Abstract] [Full Text] [PDF]

				C. Nicolaides, S. Dimou, and N. Pavlidis Prognostic Factors in Aggressive Non-Hodgkin's Lymphomas Oncologist, June 1, 1998; 3(3): 189 - 197. [Abstract] [Full Text]